Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 28 Apr 2023 |
| Orion Group Interim Report 1-3/2023 | 27 Apr 2023 |
| Orion publishes Interim Report for January-March 2023 on Thursday 27 April 2023 | 13 Apr 2023 |
| Orion is building a unique pharmaceutical research ecosystem in Finland - using data and artificial intelligence to shorten the development time of new innovative medicines | 30 Mar 2023 |
| Comparative net sales data for 2022 under Orion's new organisational structure and revised accounting practice as of 1 January 2023 | 27 Mar 2023 |